BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Mid Cap
1. Is Zydus Lifesciences Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Zydus Lifesciences Ltd is a good quality company.
2. Is Zydus Lifesciences Ltd undervalued or overvalued?
The key valuation ratios of Zydus Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Zydus Lifesciences Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Zydus Lifesciences Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||14.2%||14.2%||18%||25.7%||14.8%||14%||11.8%||7.4%||12.4%||10.5%||-|
|Value Creation Index ⓘ||0.1||0.3||0.6||1.3||0.3||0.2||0.1||-0.3||0.1||-0.1||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||13.6%||19.8%||9%||-0.5%||27%||10.6%||8.3%||1.1%||6%||-|
|Adj EPS ⓘ||6.4||7.7||11.3||18.9||14.4||17.4||18.2||11.9||22.5||21.1||20.4|
|YoY Gr. Rt. %||-||19.7%||46.8%||67.9%||-23.6%||20.6%||4.3%||-34.5%||89.5%||-6.2%||-|
|BVPS (₹) ⓘ||28.8||33.6||41.5||55.7||68||85.4||101.4||101.3||126.9||166||170.4|
|Adj Net Profit ⓘ||656||785||1,153||1,936||1,478||1,782||1,859||1,217||2,307||2,163||2,061|
|Cash Flow from Ops. ⓘ||603||903||994||1,894||1,312||919||1,282||2,932||3,294||2,104||-|
|Debt/CF from Ops. ⓘ||4.8||3||2.7||1.3||4||5.9||6.2||2.7||1.4||2||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||14.2%||7.9%||5.2%||-6.2%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||23.7||24.6||30||38.9||23.4||22.7||19.4||11.7||19.7||14.4||12.1|
|Op. Profit Mgn % ⓘ||17.8||16.6||20.3||24.7||20.3||23.9||22.7||19.6||23.6||21.8||21.1|
|Net Profit Mgn % ⓘ||10.9||11.3||13.7||20.4||15.7||14.7||14.1||8.5||16||14.7||13.1|
|Debt to Equity ⓘ||1||0.8||0.6||0.4||0.8||0.6||0.8||0.8||0.4||0.3||-|
|Working Cap Days ⓘ||155||155||153||158||178||185||213||210||103||107||0|
|Cash Conv. Cycle ⓘ||74||66||61||53||63||80||101||103||10||18||0|
No data to display
Return on Equity has declined versus last 3 years average to 12.10%
Sales growth has been subdued in last 3 years 5.06%
Net Profit has been subdued in last 3 years 5.18%
Sales growth is not so good in last 4 quarters at 7.68%
|TTM EPS (₹)||12.7||20.4|
|TTM Sales (₹ Cr.)||7,903||15,767|
|BVPS (₹.) ⓘ||129.8||170.4|
|Reserves (₹ Cr.) ⓘ||13,042||17,149|
|From the Market|
|52 Week Low / High (₹)||319.40 / 494.95|
|All Time Low / High (₹)||5.53 / 673.70|
|Market Cap (₹ Cr.)||49,750|
|Equity (₹ Cr.)||101.2|
|Face Value (₹)||1|
|Industry PE ⓘ||36.2|
Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.
The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.
Business area of the company
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.
Business verticals / products